Ibio Inc (IBIO) Stock Price, Quote & News

Company Profile

iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies agai...

Industry: Biotechnology

Sector: Healthcare

Phone: 979 446 0027

Website: ibioinc.com

Address:

11750 Sorrento Valley Road, Suite 200, San Diego, United States

Retail_Lives_Matter Jun. 24 at 4:33 PM

$IBIO F it, bought 3K more in my burner account to flip

1 · Reply

TortillaDePatata Jun. 23 at 2:20 PM

$IBIO

0 · Reply

Rower5oh Jun. 18 at 12:42 AM

$IBIO

0 · Reply

BioRich Jun. 16 at 4:42 AM

$SABS As this has all the feels of breaking out, I decided to look at the management team. Strong. In particular, I like a Chief Medical Officer with the experience and Big Pharma ties that $SABS's CMO has. $TEVA $SNY $PFE $IBIO . Looks good to me. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!

1 · Reply

Retail_Lives_Matter Jun. 9 at 4:32 PM

$IBIO go back to the 1.40’s you POS so I can buy more like an absolute moron

1 · Reply

WZMAN7227 Jun. 7 at 5:45 PM

$IBIO https://www.medpagetoday.com/meetingcoverage/asco/121604

0 · Reply

investimakerrr Jun. 5 at 2:44 PM

$IBIO

1 · Reply

dcpanda Jun. 5 at 2:26 PM

$IBIO got the volume. Next leg up coming

1 · Reply

SouthSideGrey Jun. 5 at 1:52 PM

$IBIO love that PT increase by Riley $6 🎲🎲

0 · Reply

BIOCOIN Jun. 5 at 1:36 PM

$IBIO up up up

1 · Reply

iBio initiated with an Outperform at Raymond James

Jun 4, 2026, 11:40 AM EDT - 20 days ago

iBio, Inc. Transcript: Jefferies Global Healthcare Conference 2026

Jun 2, 2026, 4:01 PM EDT - 22 days ago

iBio to Participate in Upcoming Healthcare Investor Conferences

2026-06-02T11:44:33.000Z - 22 days ago

iBio doses first participant in IBIO-600 trial

Jun 2, 2026, 7:00 AM EDT - 22 days ago

iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity

May 15, 2026, 7:00 AM EDT - 5 weeks ago

iBio, Inc. Slides: Corporate presentation

2026-05-12T21:36:01.000Z - 6 weeks ago

iBio reports Q3 EPS (7c), consensus (6c)

May 12, 2026, 4:05 PM EDT - 6 weeks ago

iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update

May 12, 2026, 4:00 PM EDT - 6 weeks ago

iBio, Inc. Earnings release: Q3 2026

May 12, 2026, 4:00 PM EDT - 6 weeks ago

iBio, Inc. Quarterly report: Q3 2026

Apr 8, 2026, 2:00 PM EDT - 2 months ago

iBio, Inc. Transcript: Status update

2026-04-08T11:12:57.000Z - 2 months ago

iBio receives regulatory clearance to initiate IBIO-600 trial in Australia

Apr 8, 2026, 7:00 AM EDT - 2 months ago

iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia

2026-03-30T16:21:02.000Z - 3 months ago

Biotech Alert: Searches spiking for these stocks today

ACOG

Mar 17, 2026, 4:00 PM EDT - 3 months ago

iBio, Inc. Transcript: Study update

2026-03-16T20:40:52.000Z - 3 months ago

iBio to provide update on cardiopulmonary program

Mar 16, 2026, 4:30 PM EDT - 3 months ago

iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Mar 9, 2026, 4:20 PM EDT - 3 months ago

iBio, Inc. Transcript: Leerink Global Healthcare Conference 2026

2026-03-09T11:10:09.000Z - 3 months ago

iBio announces new preclinical data from study evaluating IBIO-610

Mar 9, 2026, 7:00 AM EDT - 3 months ago

iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss

Mar 9, 2026, 7:00 AM EDT - 3 months ago

iBio, Inc. Slides: Corporate presentation

2026-03-02T21:34:02.000Z - 4 months ago

iBio initiated with a Buy at JonesResearch

2026-02-27T21:36:51.000Z - 4 months ago

iBio files $200M mixed securities shelf

2026-02-27T16:00:56.000Z - 4 months ago

Biotech Alert: Searches spiking for these stocks today

Feb 27, 2026, 7:00 AM EST - 4 months ago

iBio, Inc. Registration statement: Registration Filing

Feb 26, 2026, 2:00 PM EST - 4 months ago

iBio, Inc. Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 24, 2026, 7:00 AM EST - 4 months ago

iBio to Participate in Upcoming Investor Conferences

2026-02-10T21:13:10.000Z - 4 months ago

iBio reports Q2 EPS (9c), consensus (6c)

Feb 10, 2026, 4:05 PM EST - 4 months ago

iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update

Feb 10, 2026, 4:00 PM EST - 4 months ago

iBio, Inc. Quarterly report: Q2 2026

Feb 10, 2026, 4:00 PM EST - 4 months ago

iBio, Inc. Earnings release: Q2 2026

Jan 30, 2026, 7:00 AM EST - 5 months ago

iBio, Inc. Registration statement: Registration Filing

2026-01-09T12:13:56.000Z - 5 months ago

iBio prices 11.06M shares at $2.35 in private placement

Jan 9, 2026, 7:00 AM EST - 5 months ago

iBio Announces $26 Million Private Placement

2026-01-08T17:16:04.000Z - 5 months ago

Biotech Alert: Searches spiking for these stocks today

2025-12-18T14:06:19.000Z - 6 months ago

iBio initiated with an Outperform at LifeSci Capital

ARWR WVE

2025-12-18T13:41:09.000Z - 6 months ago

iBio initiated with an Outperform at LifeSci Capital

2025-12-11T16:45:34.000Z - 6 months ago

Biotech Alert: Searches spiking for these stocks today

CAMP

2025-12-10T15:25:54.000Z - 7 months ago

Biotech Alert: Searches spiking for these stocks today

Dec 4, 2025, 8:45 AM EST - 7 months ago

iBio, Inc. Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 24, 2025, 4:15 PM EST - 7 months ago

iBio to Participate in the 8th Annual Evercore Healthcare Conference

Nov 17, 2025, 7:00 AM EST - 7 months ago

iBio, Inc. Slides: Corporate presentation

Nov 12, 2025, 4:01 PM EST - 8 months ago

iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update

Nov 12, 2025, 4:00 PM EST - 8 months ago

iBio, Inc. Earnings release: Q1 2026

Nov 12, 2025, 4:00 PM EST - 8 months ago

iBio, Inc. Quarterly report: Q1 2026

Nov 10, 2025, 8:30 AM EST - 8 months ago

iBio, Inc. Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Oct 30, 2025, 7:00 AM EDT - 8 months ago

iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance

Oct 23, 2025, 7:00 AM EDT - 8 months ago

iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Oct 21, 2025, 7:00 AM EDT - 8 months ago

iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025

Oct 6, 2025, 8:00 AM EDT - 9 months ago

iBio, Inc. Proxy statement: Proxy Filing

Sep 16, 2025, 7:00 AM EDT - 10 months ago

iBio, Inc. Slides: Corporate Presentation

Sep 5, 2025, 9:00 AM EDT - 10 months ago

iBio, Inc. Annual report: Q4 2025

Sep 5, 2025, 9:00 AM EDT - 10 months ago

iBio, Inc. Earnings release: Q4 2025

Sep 5, 2025, 7:30 AM EDT - 10 months ago

iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

Aug 25, 2025, 7:00 AM EDT - 10 months ago

iBio Announces Closing of $50 Million Public Offering

Aug 19, 2025, 8:01 AM EDT - 11 months ago

iBio Announces Pricing of $50 Million Public Offering

Aug 18, 2025, 4:01 PM EDT - 11 months ago

iBio Announces Proposed Public Offering

Jun 24, 2025, 8:30 AM EDT - 1 year ago

iBio, Inc. Transcript: Study Update

Jun 24, 2025, 8:30 AM EDT - 1 year ago

iBio, Inc. Press release: Study Update

Jun 24, 2025, 8:30 AM EDT - 1 year ago

iBio, Inc. Slides: Study Update

Jun 24, 2025, 7:00 AM EDT - 1 year ago

iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results

Jun 23, 2025, 4:15 PM EDT - 1 year ago

iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call

Jun 16, 2025, 7:00 AM EDT - 1 year ago

iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment

Jun 13, 2025, 8:00 AM EDT - 1 year ago

iBio, Inc. Registration statement: Registration Filing

May 5, 2025, 8:00 AM EDT - 1 year ago

iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model

May 2, 2025, 8:00 AM EDT - 1 year ago

iBio Reports Fiscal Third Quarter 2025 Financial Results

May 2, 2025, 8:00 AM EDT - 1 year ago

iBio, Inc. Quarterly report: Q3 2025

May 2, 2025, 8:00 AM EDT - 1 year ago

iBio, Inc. Earnings release: Q3 2025

Apr 29, 2025, 1:43 PM EDT - 1 year ago

iBio Raises $6.2 Million Through Warrant Inducement Transaction

Apr 22, 2025, 8:00 AM EDT - 1 year ago

iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio

Apr 7, 2025, 7:00 AM EDT - 1 year ago

iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline

Feb 19, 2025, 4:05 PM EST - 1 year ago

iBio to Begin Trading on the Nasdaq Stock Exchange

Feb 10, 2025, 4:05 PM EST - 1 year ago

iBio Reports Fiscal Second Quarter 2025 Financial Results

Feb 10, 2025, 4:00 PM EST - 1 year ago

iBio, Inc. Quarterly report: Q2 2025

Feb 10, 2025, 4:00 PM EST - 1 year ago

iBio, Inc. Earnings release: Q2 2025

Jan 31, 2025, 7:00 AM EST - 1 year ago

iBio, Inc. Registration statement: Registration Filing

Jan 2, 2025, 7:00 AM EST - 1 year ago

iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio

Nov 12, 2024, 4:05 PM EST - 1 year ago

iBio Reports Fiscal First Quarter 2025 Financial Results

Nov 12, 2024, 4:00 PM EST - 1 year ago

iBio, Inc. Quarterly report: Q1 2025

Nov 12, 2024, 4:00 PM EST - 1 year ago

iBio, Inc. Earnings release: Q1 2025

Oct 10, 2024, 8:00 AM EDT - 1 year ago

iBio, Inc. Proxy statement: Proxy Filing

Sep 20, 2024, 4:05 PM EDT - 1 year ago

iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Sep 20, 2024, 4:00 PM EDT - 1 year ago

iBio, Inc. Earnings release: Q4 2024

Sep 20, 2024, 4:00 PM EDT - 1 year ago

iBio, Inc. Annual report: Q4 2024

Aug 12, 2024, 4:30 PM EDT - 2 years ago

iBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business Development

Jul 25, 2024, 8:00 AM EDT - 2 years ago

iBio, Inc. Registration statement: Registration Filing

Jul 3, 2024, 8:00 AM EDT - 2 years ago

iBio, Inc. Registration statement: Registration Filing

Jun 3, 2024, 7:00 AM EDT - 2 years ago

iBio Closes Sale of Manufacturing Facility in Texas

May 14, 2024, 4:00 PM EDT - 2 years ago

iBio, Inc. Quarterly report: Q3 2024

May 14, 2024, 4:00 PM EDT - 2 years ago

iBio, Inc. Earnings release: Q3 2024

May 13, 2024, 4:05 PM EDT - 2 years ago

iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

Apr 16, 2024, 8:00 AM EDT - 2 years ago

iBio, Inc. Registration statement: Registration Filing

Mar 27, 2024, 2:43 PM EDT - 2 years ago

iBio stock nearly tripled on Wednesday: here's why

Mar 27, 2024, 8:30 AM EDT - 2 years ago

iBio, Inc. Transcript: Collaboration

Mar 27, 2024, 8:30 AM EDT - 2 years ago

iBio, Inc. Press release: Collaboration

Mar 27, 2024, 7:00 AM EDT - 2 years ago

iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases

Mar 26, 2024, 7:35 PM EDT - 2 years ago

iBio Announces $15.0 Million Private Placement

Feb 26, 2024, 7:45 AM EST - 2 years ago

iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka

Feb 9, 2024, 4:00 PM EST - 2 years ago

iBio, Inc. Quarterly report: Q2 2024

Feb 9, 2024, 4:00 PM EST - 2 years ago

iBio, Inc. Earnings release: Q2 2024

Jan 16, 2024, 8:15 AM EST - 2 years ago

iBio Announces Participation in 23rd Annual PepTalk Conference

Dec 26, 2023, 7:15 AM EST - 2 years ago

iBio Amends and Extends Maturity of Credit Agreement

Dec 5, 2023, 8:00 AM EST - 2 years ago

iBio, Inc. Announces Pricing of $4.5 Million Public Offering

Nov 30, 2023, 7:00 AM EST - 2 years ago

iBio, Inc. Registration statement: Registration Filing

Nov 27, 2023, 5:20 PM EST - 2 years ago

iBio Announces Reverse Stock Split

Nov 14, 2023, 7:00 AM EST - 2 years ago

iBio, Inc. Quarterly report: Q1 2024

Nov 14, 2023, 7:00 AM EST - 2 years ago

iBio, Inc. Earnings release: Q1 2024

Nov 1, 2023, 8:24 AM EDT - 2 years ago

iBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific

Oct 27, 2023, 8:00 AM EDT - 2 years ago

iBio, Inc. Registration statement: Registration Filing

Oct 26, 2023, 8:00 AM EDT - 2 years ago

iBio, Inc. Proxy statement: Proxy Filing

Oct 16, 2023, 8:00 AM EDT - 2 years ago

iBio, Inc. Proxy statement: Proxy Filing

Oct 2, 2023, 6:45 AM EDT - 2 years ago

iBio Explains Recent Filing of Registration Statement

Sep 27, 2023, 4:19 PM EDT - 2 years ago

iBio Announces Filing of 2023 Annual Report on SEC Form 10-K

Sep 27, 2023, 4:00 PM EDT - 2 years ago

iBio, Inc. Annual report: Q4 2023

Sep 21, 2023, 4:05 PM EDT - 2 years ago

iBio Announces Amendment to Credit Agreement with Woodforest

Aug 14, 2023, 4:15 PM EDT - 3 years ago

iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development

Aug 7, 2023, 8:00 AM EDT - 3 years ago

iBio, Inc. Registration statement: Registration Filing

Jun 27, 2023, 8:00 AM EDT - 3 years ago

iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company's Next Stage of Growth

Jun 12, 2023, 4:15 PM EDT - 3 years ago

iBio Forges Research Collaboration with the National Institutes of Health

May 9, 2023, 4:30 PM EDT - 3 years ago

iBio to Participate in the JMP Securities Life Sciences Conference

Retail_Lives_Matter Jun. 24 at 4:33 PM

$IBIO F it, bought 3K more in my burner account to flip

1 · Reply

TortillaDePatata Jun. 23 at 2:20 PM

$IBIO

0 · Reply

Rower5oh Jun. 18 at 12:42 AM

$IBIO

0 · Reply

BioRich Jun. 16 at 4:42 AM

1 · Reply

Retail_Lives_Matter Jun. 9 at 4:32 PM

$IBIO go back to the 1.40’s you POS so I can buy more like an absolute moron

1 · Reply

WZMAN7227 Jun. 7 at 5:45 PM

$IBIO https://www.medpagetoday.com/meetingcoverage/asco/121604

0 · Reply

investimakerrr Jun. 5 at 2:44 PM

$IBIO

1 · Reply

dcpanda Jun. 5 at 2:26 PM

$IBIO got the volume. Next leg up coming

1 · Reply

SouthSideGrey Jun. 5 at 1:52 PM

$IBIO love that PT increase by Riley $6 🎲🎲

0 · Reply

BIOCOIN Jun. 5 at 1:36 PM

$IBIO up up up

1 · Reply

Retail_Lives_Matter Jun. 4 at 6:59 PM

$IBIO

0 · Reply

Retail_Lives_Matter Jun. 4 at 3:03 AM

$IBIO so beautiful Marty….and yet your shareholders continue to eat 💩

3 · Reply

skitime Jun. 3 at 5:47 PM

$IBIO but what about the Ebola vaccine 🤷‍♂️

0 · Reply

focafoca99 Jun. 2 at 8:10 PM

$IBIO heads to the Jefferies Global Healthcare Conference on June 4 and the Leerink Partners Therapeutics Forum in July. https://www.rapidticker.com/news/ibio-ibio-to-participate-in-upcoming-0ec7fa

0 · Reply

Rower5oh Jun. 2 at 8:10 PM

$IBIO “iBio is a clinical company now!!!” Price drops 7% 🤦‍♂️

1 · Reply

diagio Jun. 2 at 7:31 PM

$HUBC This idiot disappeared for 2 years when he lost his as on $IBIO he will disappear for another 2 years again. Look at his post history. 🤣

0 · Reply

Retail_Lives_Matter Jun. 2 at 6:40 PM

$IBIO remember when that POFS Tom said becoming a clinical stage company would be a major inflection point? I hope he stubs his toe really hard today.

1 · Reply

Bevobrack Jun. 2 at 6:35 PM

$IBIO most news like this would warrant some interest and an uptick but not our IBIO lol. Wow. 😑

0 · Reply

Magglo Jun. 2 at 6:27 PM

$IBIO ????

1 · Reply

Retail_Lives_Matter Jun. 2 at 12:22 PM

$IBIO

0 · Reply

focafoca99 Jun. 2 at 11:26 AM

$IBIO reports its first participant dosed in a Phase 1 trial, marking its transition to a clinical-stage biotech. https://www.rapidticker.com/news/ibio-ibio-becomes-a-clinical-stage-c4d62a

0 · Reply

leswa Jun. 1 at 4:06 AM

$IBIO this is literally .01 from a few years ago. What a scam.

0 · Reply

Market Cap	86.44M
Revenue (ttm)	400,000.00
Net Income (ttm)	-18.38M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-4,595.00%
Debt to Equity Ratio	0.00

Volume	402,000
Avg Vol	902,860
Day's Range	N/A - N/A
Shares Out	49.68M
Stochastic %K	57%
Beta	1.26
Analysts	Strong Sell
Price Target	$5.58